Compare Novartis with ALEMBIC LTD - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs ALEMBIC LTD - Comparison Results

NOVARTIS     Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

ALEMBIC LTD 
   Change

Alembic Limited, in its 99 years of existence, has evolved from being a tincture manufacturer to one of the prominent indigenous pharma companies in India. It is among the top players in the macrolides (anti-infective) and anti-microbials (animal hea... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NOVARTIS ALEMBIC LTD NOVARTIS/
ALEMBIC LTD
 
P/E (TTM) x 769.6 52.3 1,470.9% View Chart
P/BV x 23.1 2.1 1,082.9% View Chart
Dividend Yield % 1.9 0.5 400.0%  

Financials

 NOVARTIS   ALEMBIC LTD
EQUITY SHARE DATA
    NOVARTIS
Mar-19
ALEMBIC LTD
Mar-18
NOVARTIS/
ALEMBIC LTD
5-Yr Chart
Click to enlarge
High Rs98072 1,361.1%   
Low Rs60034 1,770.5%   
Sales per share (Unadj.) Rs198.74.7 4,227.9%  
Earnings per share (Unadj.) Rs21.06.1 343.5%  
Cash flow per share (Unadj.) Rs22.36.2 356.4%  
Dividends per share (Unadj.) Rs10.000.20 5,000.0%  
Dividend yield (eoy) %1.30.4 335.1%  
Book value per share (Unadj.) Rs307.540.7 756.2%  
Shares outstanding (eoy) m24.69267.03 9.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.011.3 35.3%   
Avg P/E ratio x37.78.7 434.4%  
P/CF ratio (eoy) x35.58.5 418.7%  
Price / Book Value ratio x2.61.3 197.3%  
Dividend payout %47.73.3 1,455.5%   
Avg Mkt Cap Rs m19,50814,139 138.0%   
No. of employees `0000.6NA-   
Total wages/salary Rs m1,171207 564.7%   
Avg. sales/employee Rs Th8,445.4NM-  
Avg. wages/employee Rs Th2,015.7NM-  
Avg. net profit/employee Rs Th891.0NM-  
INCOME DATA
Net Sales Rs m4,9071,255 390.9%  
Other income Rs m783370 211.4%   
Total revenues Rs m5,6891,625 350.0%   
Gross profit Rs m123111 110.5%  
Depreciation Rs m3238 84.1%   
Interest Rs m162 935.3%   
Profit before tax Rs m858442 194.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m01,212 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m34024 1,419.6%   
Profit after tax Rs m5181,630 31.8%  
Gross profit margin %2.58.9 28.3%  
Effective tax rate %39.65.4 731.2%   
Net profit margin %10.6129.8 8.1%  
BALANCE SHEET DATA
Current assets Rs m8,0551,867 431.4%   
Current liabilities Rs m1,850591 312.9%   
Net working cap to sales %126.4101.6 124.4%  
Current ratio x4.43.2 137.9%  
Inventory Days Days4594 47.8%  
Debtors Days Days3474 46.1%  
Net fixed assets Rs m1501,791 8.4%   
Share capital Rs m123534 23.1%   
"Free" reserves Rs m7,46910,324 72.3%   
Net worth Rs m7,59210,858 69.9%   
Long term debt Rs m041 0.0%   
Total assets Rs m9,82411,591 84.8%  
Interest coverage x54.9260.9 21.1%   
Debt to equity ratio x00 0.0%  
Sales to assets ratio x0.50.1 461.2%   
Return on assets %5.414.1 38.6%  
Return on equity %6.815.0 45.4%  
Return on capital %11.515.2 75.8%  
Exports to sales %01.5 0.0%   
Imports to sales %021.0 0.0%   
Exports (fob) Rs mNA19 0.0%   
Imports (cif) Rs mNA263 0.0%   
Fx inflow Rs m5819 296.9%   
Fx outflow Rs m1,326264 502.7%   
Net fx Rs m-1,269-244 519.1%   
CASH FLOW
From Operations Rs m-1,943236 -823.9%  
From Investments Rs m2,742-224 -1,224.2%  
From Financial Activity Rs m-298-27 1,121.1%  
Net Cashflow Rs m501-15 -3,387.2%  

Share Holding

Indian Promoters % 0.0 64.0 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 2.0 0.2 1,000.0%  
FIIs % 1.6 9.7 16.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.5 26.1 82.4%  
Shareholders   41,647 54,701 76.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NOVARTIS With:   TTK HEALTHCARE  SUVEN LIFESCIENCES  CIPLA  ELDER PHARMA  VENUS REMEDIES  

Compare NOVARTIS With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Above 30,000 Level, Gold Hits Record High, and Top Cues in Focus Today(Pre-Open)

Indian share markets ended on a strong note yesterday. The BSE Sensex and NSE Nifty rose over 8.5% yesterday, posting their biggest single-day gain.

Related Views on News

NOVARTIS Announces Quarterly Results (3QFY20); Net Profit Down 39.9% (Quarterly Result Update)

Feb 17, 2020 | Updated on Feb 17, 2020

For the quarter ended December 2019, NOVARTIS has posted a net profit of Rs 77 m (down 39.9% YoY). Sales on the other hand came in at Rs 1 bn (down 13.4% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

ALEMBIC LTD Announces Quarterly Results (1QFY20); Net Profit Down 70.9% (Quarterly Result Update)

Aug 27, 2019 | Updated on Aug 27, 2019

For the quarter ended June 2019, ALEMBIC LTD has posted a net profit of Rs 20 m (down 70.9% YoY). Sales on the other hand came in at Rs 260 m (down 41.5% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

NOVARTIS Announces Quarterly Results (1QFY20); Net Profit Down 92.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NOVARTIS has posted a net profit of Rs 8 m (down 92.1% YoY). Sales on the other hand came in at Rs 1 bn (down 20.8% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

NOVARTIS Announces Quarterly Results (4QFY19); Net Profit Down 26.2% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, NOVARTIS has posted a net profit of Rs 195 m (down 26.2% YoY). Sales on the other hand came in at Rs 1 bn (down 11.9% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

ALEMBIC LTD Announces Quarterly Results (4QFY19); Net Profit Down 14.6% (Quarterly Result Update)

May 17, 2019 | Updated on May 17, 2019

For the quarter ended March 2019, ALEMBIC LTD has posted a net profit of Rs 40 m (down 14.6% YoY). Sales on the other hand came in at Rs 253 m (down 23.8% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

More Views on News

Most Popular

Sorry Warren Buffett, I'm Following This Man Instead of You in 2020(The 5 Minute Wrapup)

Mar 30, 2020

This man warned of an impending market correction while everyone else was celebrating the renewed optimism in early 2020...

The Biggest Trading Opportunity of 2020 is Here...

Mar 26, 2020

India's #1 trader, Vijay Bhambwani, talks about a hugely profitable trading opportunity which you must know about today!

One Stock that is All Charged Up for the Post Coronavirus Rebound(The 5 Minute Wrapup)

Apr 1, 2020

A stock with strong moat is currently trading near 5-year lows.

The Insiders See a Buying Opportunity in These Smallcaps Amid Coronavirus Outbreak(Profit Hunter)

Mar 31, 2020

The promoters are buying these smallcaps amid the coronavirus outbreak.

How to Identify a Market Rebound(Fast Profits Daily)

Mar 27, 2020

This very useful indicator can spot a market bottom.

More

How to Trade the
Coronavirus Crash

Coronavirus Crash
Get this special report, authored by Equitymaster's top analysts, now.
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Apr 7, 2020 (Close)

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE NOVARTIS WITH

MARKET STATS